Current calls, week 7, 2023

European calls

Research Grants - Human Frontier Science Program Organization

HFSP Research Grants support innovative basic research into fundamental biological problems with emphasis placed on novel and interdisciplinary approaches that involve scientific exchanges across national and disciplinary boundaries.

Research grants are provided for teams of scientists from different countries who wish to combine their expertise in innovative approaches to questions that could not be answered by individual laboratories. Preliminary results are not required and applicants are expected to develop new lines of research through the research collaboration.

Two types of Grant are available:

• Research Grants – Program (RG-Program): to allow teams of independent researchers to develop new lines of research through a new collaboration, with applications including independent investigators early in their careers being particularly encouraged;
• Research Grants – Early Career: to enable teams of young investigators who are directing a research group to initiate and direct their own independent lines of research.

Closing date (Letter of Intent): 21 March 2023

More information

Young investigator programme - European Molecular Biology Organisation (EMBO)

The European Molecular Biology Organisation invites applications for its young investigator programme. This supports life scientists who have been group leaders for less than four years at the time of application in setting up their laboratories. Young Investigators receive financial support for networking for four years and benefit from training opportunities, support for their lab members and mentoring. They become part of an international network of more than 600 current and former EMBO Young Investigators, Installation Grantees and Global Investigators.

Closing date: 01 April 2023

More information

Andrew K Burroughs short-term training fellowship - European Association for the Study of the Liver (EASL)

The European Association for the Study of the Liver invites applications for the Andrew K Burroughs short-term training fellowship programme. This enables postgraduate investigators, who intend to spend time at a foreign institution in Europe, to accomplish a very focused research project, to learn an experimental procedure or methodology, or to get in-depth knowledge about a sophisticated, clinical diagnostic procedure not available at their home institution.

Members of the association who hold an MD or PhD degree and are no more than 40 years of age may apply. They may be of any nationality and be both basic or clinical investigators. The research supervisor at the hosting institution must be a member of the association but must not be a member of its governing board. No more than one application per hosting and home department is considered for a period of two years following the grant allocation.

Fellowships are worth €3,000 per month for up to six months.

Closing date: 30 March 2023

More information

International 3Rs prize - National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)

The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) invites nominations for its international 3Rs prize. This recognises an original medical, biological or veterinary research paper published in the last three years that has or could have major impacts on the replacement, refinement or reduction of the use of animals in research

Closing date: 05 April 2023

More information

US calls

Federal Funding agencies

Notice of Special Interest: Collaborative Studies on Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD): NIH

This Notice of Special Interest (NOSI) facilitates collaborative, cross-disciplinary, and multi-institutional approaches that will contribute new and vital information and insights about normal aging and the clinical and pathological course of AD/ADRD and/or that can advance the research agendas in any of the eight focus areas outlined in the AD/ADRD Research Implementation Milestones. Specifically, this NOSI solicits R01 applications that address its overarching objectives: 1) to promote the wider sharing and leveraging of NIA’s existing AD/ADRD resources by facilitating access to unique resources (such as the availability of neuropathological data on thousands of participants) and the collection and integration of new data and samples, and 2) to broaden the participation of researchers in the design, analysis, and interpretation of results from collaborative research that makes use of these unique resources to answer novel scientific questions.

Application and Submission Information: This notice applies to due dates through November 13, 2024.

Submit applications for this initiative using the following funding opportunity announcement (FOA) or any reissue of the announcement through the expiration date of this notice.

• PAR-22-093 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)

Notice Number: NOT-AG-21-035

Further information

2023 Amyotrophic Lateral Sclerosis Research Program (Congressionally Directed Medical Research Programs): DoD

The FY23 appropriation is $40.0M. Currently there are four award mechanisms are being solicited.

• Pilot Clinical Trial Award
  • Supports exploratory clinical trials of novel therapeutics to demonstrate feasibility and inform the design of more advanced trials in amyotrophic lateral sclerosis (ALS).
  • Must support a clinical trial and may not be used for preclinical research studies.
  • The maximum allowable funding for the entire period of performance is $1,000,000 to $2,000,000 for direct costs and up to three years.
  •  
• Clinical Biomarker Development Award
  • Supports development or improvement of clinical biomarkers to enrich clinical trials in ALS.
  • The maximum allowable funding for the entire period of performance is $750,000 for direct costs and up to two years.
  •  
• Therapeutic Development Award
• • Supports secondary preclinical validation and Investigational New Drug (IND)-enabling studies of therapeutics for ALS.
  • The maximum allowable funding for the entire period of performance is $1,500,000 for direct costs and up to three years.
  •  
• Therapeutic Idea Award
  • Supports highly innovative, hypothesis-driven preclinical therapeutic development in ALS.
  • The maximum allowable funding for the entire period of performance is $600,000 to $750,000 for direct costs and up to two years.

Deadlines:

• Pilot Clinical Trial Award: April 13, 2023 (Pre-application); July 13, 2023 (Full application).
• Clinical Biomarker Development Award: April 13, 2023 (Pre-application); July 13, 2023 (Full application).

• Therapeutic Development Award: April 13, 2023 (Pre-application); July 13, 2023 (Full application).
• Therapeutic Idea Award: April 13, 2023 (Pre-application); July 13, 2023 (Full application).

Funding Opportunity Announcement (FOA):

• Pilot Clinical Trial Award: HT9425-23-ALSRP-PCTA

• Clinical Biomarker Development Award: HT9425-23-ALSRP-CBDA
• Therapeutic Development Award: HT9425-23-ALSRP-TDA
• Therapeutic Idea Award: HT9425-23-ALSRP-TIA

Further informtion 

2023 Epilepsy Research Program (Congressionally Directed Medical Research Programs): DoD

The FY23 appropriation is $12.0M. The ERP encourages collaboration among post-traumatic epilepsy (PTE) researchers and urges the scientific community to utilize equitable partnerships with people living with PTE to maximize the translational and impact potential of proposed research.

Funding Opportunity Announcement (FOA):

• Idea Development Award
  • This is to solicit novel, innovative research that has the potential to increase our understanding of PTE to improve quality of life, especially in Service Members, Veterans, and/or their care partners. The work should innovatively challenge existing research paradigms or exhibit high levels of creativity. 
  • The maximum allowable funding for the entire period of performance is $450,000 to $650,000 for direct costs and up to three years.
• Research Partnership Award
  • To create an avenue to support new or existing collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts. It is expected that investigators utilize their distinct but complementary perspectives to synergistically address a central problem or question critical to PTE research and those living with PTE, their families, and/or their care partners.
  • The maximum allowable funding for the entire period of performance is $1,200,000 for direct costs and up to three years.
  •  
• Virtual Post-Traumatic Epilepsy Research Center Faculty Award
  • The P-TERC is a unique, interactive virtual research center providing intensive mentoring, national networking, collaborations, and a peer group for new PTE investigators. The overarching goal of the Virtual P-TERC is to develop successful, highly productive PTE researchers in a collaborative research and career development environment to enhance quality and expand quantity of the PTE research field.
  • The maximum allowable funding for the entire period of performance is $525,000 for direct costs and up to three years.
  •  
• Leveraging Research Award
  • To support research that leverages ongoing or completed research studies for which PTE was not an original focus and to provide support to expand the research to develop such a focus and increase our understanding of PTE. The project may include basic, translational, and/or clinical research studies.
  • The maximum allowable funding for the entire period of performance is $250,000 for direct costs and up to three years.

Deadlines:

• Idea Development Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full proposal).
• Research Partnership Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full proposal).
• Virtual Post-Traumatic Epilepsy Research Center Faculty Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full proposal).
• Leveraging Research Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full proposal).

Funding Opportunity Announcement (FOA):

• Idea Development Award: HT9425-23-ERP-IDA
• Research Partnership Award: HT9425-23-ERP-RPA
• Virtual Post-Traumatic Epilepsy Research Center Faculty Award: HT9425-23-ERP-VIRTUAL-P-TERC-F
• Leveraging Research Award: HT9425-23-ERP-LRA   

Further information 

In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed): NIH

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. The current (July 19, 2022) IMPC data release includes phenotypic data for 8260 knockout genes. Overall, the IMPC hopes to generate a null mutant and undertake broad-based phenotyping for every gene in the mouse genome. About 30% of these strains are expected to be either embryonic or perinatal lethal, or subviable. However, a large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research.

Deadline: standard due dates until January 08, 2026. Applications are due by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PAR-23-074

Further information

Early and Late Stage Clinical Trials for the Spectrum of Alzheimer’s Disease/Alzheimer’s Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional): NIH

The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite applications that propose to develop and implement early to late stage clinical trials of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.

Deadline: standard due dates until January 08, 2025. Applications are due by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA):  PAR-23-081

Further information

Foundations

2023 Requests for Proposals, Lung Cancer Research Foundation(LCRF), US

The LCRF grant program provides funding for research into the prevention, diagnosis, treatment and cure of lung cancer. 

• LCRF Leading Edge Research Grant Program:
  • o This program seeks to fund innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, early detection, disparities, and social determinants of health research. This funding mechanism seeks novel ideas, approaches, methods, and techniques that promise to have a profound impact on lung cancer patients and their treatment teams.
• LCRF Minority Career Development Award (CDA) in Lung Cancer
  • This program is a two-year career development award intended to support early-stage scientists from underrepresented groups working in lung cancer in diverse areas of research including basic, clinical, translational, disparities, and social determinants of health research.
• LCRF Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer
  • This program is focused on identifying, characterizing, and developing approaches that will detect lung cancer at the earliest stages.
• LCRF Research Grants on Understanding Resistance in Lung Cancer
  • This program will focus on understanding resistance and support research projects with an emphasis on characterizing, identifying, treating, overcoming, or preventing resistance to therapies in lung tumor cells, tissues, mouse models, or patients.

Each of these funding mechanisms will award $150,000 over two years for selected projects, and all mechanisms except the LCRF Minority Career Development Award will be reviewed through a two-step process (LoI and Full proposal).

Deadlines: March 10, 2023 (Letter of Intent). Full proposal is selected by invitation only.

LCRF Minority Career Development Award: May 31, 2023 (Full Proposal)

Further information

Alzheimer's Association Research Grant - New to the Field (AARG-NTF), US

The AARG-NTF grant program aims to fund investigators who are new to Alzheimer's and all other dementia fields of research, including neuroscience or neurodegeneration (Alzheimer's, Parkinson's, Lewy body dementia, etc.), and provide them with funding to establish a research path in Alzheimer's and all other dementias, to develop preliminary or pilot data, to test procedures and to develop hypotheses. Each AARG-NTF award total is limited to $200,000 (direct and indirect costs) for up to three years

Deadlines: March 6, 2023 (Letter of Intent); May 4, 2023 (Full proposal); Prior to August 30, 2023 (Award Notification).

Further information